Social interaction and functional status among community-dwelling older adults in Japan: a longitudinal study during the coronavirus disease 2019 pandemic. [PDF]
Zhang J +9 more
europepmc +1 more source
Developmental and aging trajectories of 40-Hz auditory steady-state responses: A systematic review across the human lifespan. [PDF]
Mockevičius A +3 more
europepmc +1 more source
Sleep disturbance is associated with greater subjective and neural negative emotionality in people with alcohol use disorder. [PDF]
Grodin EN +3 more
europepmc +1 more source
Inter-Stimulus-Interval Dependence in Auditory Cortex Reflects Perceptual Organization of Streams Under Informational Masking. [PDF]
Raudonat C, Doroszewski E, Gutschalk A.
europepmc +1 more source
Ion dynamics underlying the seizure delay effect of low-frequency electrical stimulation. [PDF]
Girier G +6 more
europepmc +1 more source
Effects of nurse-led cognitive behavioral therapy on insomnia in adults: a meta-analysis. [PDF]
Bai T +6 more
europepmc +1 more source
Related searches:
Abstract Golgi’s cultural formation was permeated by positivism. For him, science was the supreme ideal to which one could consecrate one’s entire life. Only science could guarantee continuous unending progress for humankind. From this perspective, metaphysical speculations had no relevance for an understanding of the human condition.
openaire +1 more source
ISIS-3521. Isis Pharmaceuticals.
Current opinion in investigational drugs (London, England : 2000), 2002ISIS-3521 is a 20-mer antisense phosphorothioate oligonucleotide PKCa expression inhibitor, under development by Isis (formerly in collaboration with Novartis) for the potential treatment of solid tumors that are refractory to, or recurrent with, standard treatment regimens [175741].
K, Li, J, Zhang
openaire +1 more source
ISIS-14803 (Isis Pharmaceuticals).
Current opinion in investigational drugs (London, England : 2000), 2002Isis and Merck are developing an antisense oligonucleotide for the potential treatment of hepatitis C virus (HCV) infection [305306]. As of March 2000, the lead from this program, ISI-14803, was being studied in a phase I/II trial where it was administered in three weekly 2-h infusions for 4 weeks [327913], [357823].
openaire +1 more source

